On June 30, 2026, the NEJM retracted the clinical trial that got a drug approved by the FDA, triggering a $3.7B acquisition by Amgen.
The reason: the primary endpoint data was manipulated.
Here's how it happened, how it came to light, and who paid the price. 🧵
@AppieAnanas@Longroaderstar i’d argue inter-EON variance is actually probably too great and sequence/mod-dependent to make any platform-based learnings on the translational PK/PD side, but sure it’d at the very least validate their internal modelling.
the year is 2037. $ALNY have entered their 12th TTR molecule into the clinic - this time with q10y dosing. the patients rejoice.
https://t.co/xqUhCmY8l7
@BiotechAnalysst if you think the reason $sgmo is priced the way it is is because of uncertainty over ST-920 efficacy, I don’t think you’ve been paying attention over the past few years
1/🚨WOW! $LLY continues to strengthen its leadership position in the Gene & RNA Editing space with its recent p announcement of a $1.9B collaboration & licensing agreement signed with Ascidian Therapeutics to develop RNA-editing therapies 🧵👇for undisclosed kidney diseases. $XBI